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Abstract
Introduction: The aim of this randomized controlled trial was to investigate whether volatile anesthetics used for
postoperative sedation have any beneficial effects on myocardial injury in cardiac surgery patients after on-pump
valve replacement.
Methods: Anesthesia was performed with propofol. After arrival in the intensive care unit (ICU), 117 patients were
randomized to be sedated for at least 4 hours with either propofol or sevoflurane. Sevoflurane was administered
by using the anesthetic-conserving device. Troponin T, creatine kinase, creatine kinase from heart muscle tissue,
myoglobin, and oxygenation index were determined on arrival at the ICU, 4 hours after sedation, and in the
morning of the first postoperative day (POD1). Primary end points were cardiac injury markers on POD1. As
secondary end points oxygenation, postoperative pulmonary complications, and ICU and hospital stay were
documented.
Results: Fifty-six patients were analyzed in the propofol arm, and 46 patients in the sevoflurane arm. Treatment
groups were comparable with regard to patient demographics and intraoperative characteristics. Concentration of
troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane
group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted
difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).
Conclusions: The data presented in this investigation indicate that late postconditioning with the volatile
anesthetic sevoflurane might mediate cardiac protection, even with a late, brief, and low-dose application.
Trial registration: ClinicalTrials.gov: NCT00924222.
Introduction
Cardiac surgery requiring extracorporeal circulation (ECC)
is a common procedure, which is used for valve repair,
valve replacement, as well as for coronary artery bypass
grafting. During ECC, the myocardium is exposed to tran-
sient ischemia, followed by reperfusion, sometimes leading
to myocardial infarction. This is linked to an increased
long-term incidence of adverse cardiovascular events [1].
Additionally, a systemic inflammatory response of various
degrees is observed with cardiopulmonary bypass, possibly
leading to systemic inflammatory response syndrome and/
or single or multiple organ dysfunctions [2-5]. Both ische-
mia-reperfusion injury and the inflammatory response
syndrome negatively affect patient outcome.
For several years, inhalational agents have been suc-
cessfully used for sedation of ventilator-dependent
patients in the intensive care unit (ICU) and have become
a valuable alternative to commonly used intravenous
drugs [6]. Studies have shown that the method of seda-
tion with volatile anesthetics [7] results in shorter time to
extubation and faster mental recovery compared with
intravenously administered sedatives [8,9]. Recently, a
new tool for postoperative volatile sedation of ventilated
patients in the ICU has been established: the Anaesthetic
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Conserving Device (AnaConDa; Sedana Medical,
Uppsala, Sweden).
The protective effects of volatile anesthetics on organ
preservation have been studied extensively. Several clinical
trials have demonstrated that volatile anesthetics decrease
cardiac injury after procedures involving the use of ECC
[10-13]. Most often, volatile anesthetics have been used in
a preconditioning manner or during the entire surgical
procedure. This randomized controlled trial, in contrast,
examined the effect of sevoflurane in a clinical setting of
late postconditioning in patients undergoing cardiac sur-
gery with ECC. Sevoflurane was therefore administered
only postoperatively by using the AnaConDa system
[14,15]. We hypothesized that late and short-time applica-
tion of sevoflurane in low anesthetic gas concentration
would attenuate myocardial ischemia-reperfusion injury
after cardiopulmonary bypass procedures and possibly
have a positive impact on pulmonary function.
Materials and methods
Study design
This is a prospective randomized parallel group trial
comparing postoperative propofol with sevoflurane seda-
tion in the ICU after on-pump cardiac surgery. All
patients between 18 and 90 years of age, scheduled for
elective cardiac surgery requiring the use of ECC at the
University Hospital Zurich, Switzerland, were eligible.
Exclusion criteria were poor cardiac baseline function,
defined as an ejection fraction of < 30%, significant cor-
onary impairment (CCS ≥ 3 or myocardial infarction
within 7 days before the surgery date), emergency proce-
dures, previous cardiac surgery, chronic pulmonary dis-
ease (FEV1 < 80% or FEV1/FVC < 70% of predicted
value), renal dysfunction (creatinine clearance, < 60 ml/
min), insulin-dependent diabetes mellitus, pregnancy,
and current steroid treatment.
Randomization was computer generated with prestra-
tification for the following surgery groups: (a) aortic
valve surgery, (b) mitral valve surgery, and (c) combined
procedures with coronary artery bypass grafting (CABG)
or replacement of the ascending aorta. The envelope
was opened by an investigator at the end of the case.
Anesthesiologists and surgeons were blinded to the
intervention.
The local ethics committee (Ethic committee, Kantonale
Ethikkommission, University Hospital Zurich, Switzerland)
approved the trial (StV 5-2007). The study was registered
in ClinicalTrials.gov as NCT00924222. Written informed
consent was obtained from all study subjects.
Anesthetic management
Preoperatively patients underwent routine clinical and
laboratory examinations. Before surgery, they received oral
midazolam at the clinical discretion of the anesthesiologist.
For the surgical procedure, patients were monitored in a
standard fashion with a five-lead electrocardiogram, pulse
oximetry, invasive blood pressure measurement, central
venous pressure measurement, bispectral index (BIS), and
transesophageal echocardiography. Direct measurement of
pulmonary artery pressure was used in more complex
cases. The cardiopulmonary bypass (CPB) technique was
nonpulsatile, using a roller pump. Active cooling was
performed, aiming at temperatures of 32°C to 34°C. Crys-
talloid cardioplegia was used without hot shot. All patients
received general anesthesia with a target-controlled infu-
sion of propofol, fentanyl boluses, plus remifentanil as a
continuous infusion. Muscular relaxation was achieved
with pancuronium at the induction of anesthesia. Volatile
anesthetics were not applied to the patient in the operat-
ing room at all. After surgery, patients were transferred to
the ICU under continuous analgosedation with propofol
and remifentanil.
ICU management
Patients in the control group received propofol titrated
by the critical care team within a range of 0.5 to 4.0
mg/kg BW per hour to achieve continuous sedation
(total intravenous application, no target-controlled infu-
sion). Propofol was started at a rate of 2 mg/kg/h and
adjusted according to the sedation score and hemody-
namics. Remifentanil at a dose of 0.05 to 0.2 μg/kg BW
per minute was added as needed to achieve analgesia. In
the treatment group, patients were switched to an inha-
lational sedation regimen with sevoflurane immediately
after arrival at the ICU. For this purpose, sevoflurane
(Sevorane; Abbot, Abbot Park, IL, USA) was applied via
the AnaConDa system at a starting dose of an age-
adjusted minimum alveolar concentration (MAC) of 0.5
[16], and was titrated to balance sedation. The end-tidal
concentration of sevoflurane was measured by using a
Dräger Scio gas module (Dräger Medical, Lübeck,
Germany). Remifentanil was applied to patients in the
sevoflurane arm at the same does as in the propofol
group (0.05 to 0.2 μg/kg/BW). The minimal duration of
sedation was 4 hours. During sedation, the patients were
monitored with five-lead electrocardiogram, pulse oxi-
metry, invasive blood pressure measurement, and central
venous pressure measurement. The AnaConDa module
was incorporated in the respiratory circuit of all patients
in both groups to control for any unknown effects of
the system itself. A CONTRAfluran active charcoal filter
(ZeoSys GmbH, Berlin, Germany) was used on the
expiratory valve of the ventilator to minimize environ-
mental contamination with sevoflurane. For mechanical
ventilation, the ventilator Evita XL (Dräger, Lübeck,
Germany) was used in biphasic positive airway pressure
(BiPAP) mode with a first positive endexpiratory pres-
sure (PEEP) of 6 cm H2O and tidal volumes of 6 to
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9 ml/kg. The settings were adjusted to maintain a
paCO2 of 5.0 to 6.0 kPa. The FiO2 was set to reach an
age-adapted paO2 between 8.5 and 10 kPa. Once the
patient fulfilled extubation criteria (adequate cardiac
function, hemodynamic stability, no coagulopathy, no
bleeding, adequate pulmonary function and respiratory
effort, including normal postoperative chest radiograph
and sufficient blood gas analysis, as judged by the inten-
sivist), the application of propofol or sevoflurane was
stopped.
Any postoperative nausea and vomiting (PONV) was
treated according to the following scheme: (a) topisetron,
2 mg, plus droperidol, 0.5 mg, intravenously (iv) applied;
(b) repeated droperidol, 0.5 mg, iv; (c) meclozin/pyri-
doxin/caffeine (50/50/20 mg) suppository; and (d) meto-
clopramide, 10 mg iv. Steroids and propofol were not used
for this purpose.
Primary and secondary outcomes
The primary outcome was defined as cardiac injury on the
first postoperative day (POD1) measured by troponin T 12
to 18 hours after surgery. Additional biochemical out-
comes were creatine kinase (CK), myocardium-specific
creatine kinase (CK-MB), and myoglobin. All laboratory
values were determined on arrival in the ICU (considered
baseline values), 4 hours after initiating postoperative
sedation in the ICU, and in the morning of POD1. The
following normal ranges are accepted for the different
parameters: troponin, < 0.014 μg/L; CK, < 190 U/L;
CK-MB, 28 to 72 U/L; and myoglobin, < 24 μg/L.
Secondary end points included oxygenation index
(paO2/FiO2) after 4 hours of sedation before extubation
and at POD1, incidence of postoperative pulmonary com-
plications (any of the following: temperature > 38.5°C plus
productive cough, radiologic signs of pneumonia or patho-
logic organisms in Gram stain or culture; initiation of
antimicrobial therapy; need for reintubation) during hospi-
talization, duration of ICU and hospital stay, and the need
for antiemetics.
To control for possible remaining confounders, the
following parameters were additionally recorded: ECC
time, aortic cross-clamp (ACC) time, and administration
of blood products.
Statistics
The study was powered to detect a difference of 0.3 U/L
in troponin on POD1 between the two groups with a
standard deviation of 0.5 U/L, a b of 0.8, and an a of
0.05. The expected number in each group was 44.
The data analyst was masked for group assignment
when performing the statistical analyses, and the rando-
mization code was broken only after the analyses were
completed. A per-protocol analysis was performed: we
analyzed all patients according to the randomization and
whether they received the randomly assigned interven-
tion. We did not include patients in the analyses who
were extubated early and who could not be sedated
appropriately, because we did not collect outcome data
for these patients.
For all continuous outcomes, unadjusted and adjusted
linear regression models were performed. For all dichoto-
mous outcomes, unadjusted and adjusted logistic regres-
sion models were calculated. The analyses were adjusted
for potential confounders. The adjusted models included
patient age, need for blood products during the case, as
well as the duration of ECC and ACC. For the cardiac
injury markers, the models also included baseline values of
the corresponding cardiac injury marker on admission to
the ICU. For the linear regression models, the distribu-
tions of the residuals were evaluated (normal distribution).
Statistical significance was defined as P < 0.05. STATA
was used for all analyses (STATA for Mac, version 12.0;
Stata Corp, College Station, TX, USA).
Results
Between October 2007 and September 2009, 884
patients were assessed for eligibility (Figure 1). Seven
hundred sixty-seven patients did not qualify for the
study, 16 refused consent, 33 were included in other
RCTs, 713 met exclusion criteria, and five patients had
received a volatile anesthetic during surgery. One hun-
dred seventeen consented and were randomized, 57
patients for sevoflurane and 60 for propofol sedation.
Eleven and 4 dropouts were found in the sevoflurane
and propofol groups, respectively: in the sevoflurane
group, 7 patients were extubated earlier than the fore-
seen 4 hours, and in 4 patients, the AnaConDa device
had to be removed because of sedation problems, and
sedation was continued with propofol. In the propofol
Figure 1 Enrollment and randomization of patients . ICU,
intensive care unit; OR, operating room; RCT, randomized controlled
trial.
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group, 4 early extubations were observed. The primary
analysis was performed with 46 patients randomized to
sevoflurane, 56 patients to propofol.
The baseline characteristics and intraoperative para-
meters are presented in Table 1. As expected with stra-
tified randomization, the distribution of the types of
surgery was even between both groups: 28 patients in
the propofol group and 27 patients in the sevoflurane
group received aortic valve surgery. Nine patients in the
propofol group and 4 patients in the sevoflurane group
had a mitral valve procedure. Nineteen patients in the
propofol group and 15 in the sevoflurane group had
combined cardiac surgery on either the aortic or the
mitral valve, together with CABG surgery or replace-
ment of the ascending aorta.
Primary outcome, troponin T on POD1, reached statis-
tical significance in the unadjusted as well as the linear
regression model, adjusted for age of the patient, ECC,
blood products, as well as the baseline troponin level. On
POD1, the mean of troponin in the sevoflurane group
was 0.4 μg/L lower than that in the propofol group (95%
CI, -0.7 to -0.1; P < 0.01). In the adjusted model, this dif-
ference reached a value of 0.2 U/L (CI, -0.4 to -0.02; P =
0.03) (Table 2). Aortic cross-clamp time was dropped
from the multiple regression model because of its non-
significant impact on the results as well as because of
concerns for collinearity with the ECC time. In the linear
regression model, values for CK reached significance on
POD1 in the unadjusted (difference, -258; CI, -434 to
-83; P < 0.01), as well as in the adjusted model (without
adjustment for ACC) (difference, 169; CI, -331 to -8; P =
0.04) (Table 2).
In the subgroup of patients with aortic valve surgery (28
in the propofol and 27 in the sevoflurane group), the fol-
lowing results were assessed: The unadjusted difference in
means between the propofol group and the sevoflurane
group was 0.5 μg/L for troponin T on POD1 (CI, -0.8 to
-0.1; P = 0.006) (Table 3). The adjusted difference in
means between the groups was 0.3 μg/L (CI, -0.6 to -0.1;
P = 0.02). The same model of multiple linear regression
was used as described earlier.
For CK values, the difference in mean value was 250
U/L at POD1 in the unadjusted model (CI, -497 to -2;
P = 0.048); after adjustment, no significant result was
obtained.
The mean oxygenation index in the sevoflurane group
was 42 points higher on POD1 compared with the propo-
fol group in the unadjusted model (P = 0.04) (Table 4).
After adjusting for age, blood products, and ECC time,
the difference decreased to 27 points and was no longer
significant. Postoperative pulmonary complications were
lower in the sevoflurane group, with an OR of 0.4, but
not statistically significant in comparison with the propo-
fol group I in either the unadjusted logistic regression
model or after adjusting for age, blood products, and
ECC time (Table 5).
The length in ICU stay and hospitalization time did
not differ between the two groups in the adjusted and
in the unadjusted model (Table 4).
Plasma creatinine levels on POD1 as well as the inci-
dence of PONV and postoperative pulmonary complica-
tions were comparable between both groups, and no
statistical significant differences were found in the
adjusted and in the unadjusted models (Tables 4 and 5).
Discussion
The main result of this randomized controlled trial is that
patients after aortic and mitral valve replacement in com-
bination with CABG or ascending aorta surgery receiving
a 4-hour sedation with the volatile anesthetic had lower
troponin T values as the most-specific cardiac injury mar-
ker at POD1 compared with propofol sedation.
Table 1 Baseline characteristics and intraoperative parameters
Sevoflurane group
(n = 46)
Propofol group
(n = 56)
Age in years (mean, SD) 63 (12.4) 64 (14.7)
Male (%) 69 67
Body mass index in kg/m2 (mean, SD) 26.6 (3.7) 27.1 (3.8)
ECC time (minutes; mean, SD) 141 (39) 152 (49)
ACC time (minutes; mean, SD) 92 (31) 101 (34)
Crystalloids (milliliters; mean, SD) 1,390 (450) 1,480 (610)
Colloids (milliliters; mean, SD) 1,490 (740) 1,420 (760)
Blood products in units (median, IQR) 0 (1) 0 (2)
Troponin T baseline (μg/L; mean, SD) 0.65 (0.6) 0.87 (0.9)
CK baseline (U/L; mean, SD) 373 (191) 493 (337)
CK-MB baseline (U/L; mean, SD) 47.5 (56.4) 50.6 (31.1)
Myoglobin baseline (μg/L; mean, SD) 359 (149) 477 (271)
ACC, aortic cross clamp; CK, creatine kinase; CK-MB, creatine kinase, heart muscle tissue; ECC, extracorporeal circulation. Baseline refers to the time-point at the
end of the case before starting the sedation with either sevoflurane or propofol.
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It is well known from experimental observations that
halogenated anesthetics exert many non-anesthetic prop-
erties, causing an endogenous adaptive response of cells
to injury, such as that of myocardiocytes to an ischemic
insult [17,18]. In open-heart surgery, myocardial ischemia
and reperfusion is an inherent and inevitable part of the
surgical procedure itself. Presence and duration of ACC
and ECC time are thereby major factors determining the
extent of the inflammatory response, injury, and finally,
impairing postoperative organ function.
Relevant protection of postoperative cardiac function
was first described in 1999 in a small clinical study that
used a preconditioning protocol with isoflurane before
cross-clamping [10]. The study revealed less release of
CK-MB and troponin, indicating attenuated cardiac
injury in the isoflurane group. The cardioprotective
potential of various volatile anesthetics, applied during
surgery, measured by a reduction in biomarkers of car-
diac injury, has been confirmed by many authors
[11-13,19,20]. A meta-analysis performed in 2007 clearly
suggested that sevoflurane or desflurane is able to reduce
the incidence of myocardial infarction and postoperative
mortality after cardiac surgery [21]. Some of these studies
even showed benefits with regard to mechanical ventila-
tion and/or length of hospital stay [12,13]. Different win-
dows of pharmacologic protection with early and late
pharmacologic preconditioning by the use of volatile
anesthetics have been described in the literature, both
probably involving different signaling pathways, which
are still not understood in detail. Reactive oxygen species,
apoptotic signaling pathways, potassium channels, intra-
cellular calcium concentration, nitric oxide, heat-shock
proteins, as well as neutrophil and platelets adhesion to
the endovascular cells appear to be involved in ischemia
and reperfusion injury [22,23].
Although the current trial focuses on a sevoflurane
intervention after on-pump cardiac surgery (postcondi-
tioning), several studies have elucidated the effect of the
application of volatile anesthetics during the whole surgi-
cal procedure, called conditioning, or preconditioning,
when applied before initiation of the ischemic phase.
Data from Cromheecke et al. [24] reveal that patients
randomized to a sevoflurane anesthesia for aortic valve
replacement have, in comparison with the propofol
Table 2 Linear regression analysis to compare cardiac markers between the sevoflurane and propofol groups (n =
102)
Cardiac marker (U/L) Unadjusted difference in means
(point estimate)
95% Cl Adjusted difference in means
(point estimate)
95% CI
Troponin T, 4 hours (μg/L) -0.3 -0.7, 0.1 -0.1 -0.2, 0.1
CK, 4 hours (U/L) -140a -250, -30 -38 -96, 20
CK-MB, 4 hours (U/L) -2.4 -23.9, 19.2 1.2 -6.4, 8.7
Myoglobin, 4 hours (μg/L) -113a -187, -39 -42 -100, 16
Troponin T, POD1 (μg/L) -0.4a -0.7, -0.1 -0.2a -0.4, -0.02
CK, POD1 (U/L) -258a -434, -83 -169a -331, -8
CK-MB, POD1 (U/L) -4.6 -27.5, 18.3 -1.1 -13.2, 11.0
Myoglobin, POD1 (μg/L) -107 -217, 3 -48 -157, 60
The model is adjusted for age, blood products, baseline value of corresponding cardiac injury marker on ICU admission, and extracorporeal circulation (ECC) time.
The propofol group is the reference. aP < 0.05, statistically significant.
4 hours, 4 hours after ICU admission; CK, creatine kinase; CK-MB, creatine kinase, heart muscle tissue; POD1, first postoperative day.
Table 3 Linear regression analysis to compare cardiac markers between sevoflurane and propofol for the subgroup
with aortic valve surgery (n = 55)
Cardiac marker (U/L) Unadjusted difference in means
(point estimate)
95% Cl Adjusted difference in means
(point estimate)
95% CI
Troponin T, 4 hours (μg/L) -0.5 -1.0, 0.0 -0.2 -0.4, 0.1
CK, 4 hours (U/L) -146a -284, -8 -46 -146, 54
CK-MB, 4 hours (U/L) -10.3 -25.1, 4.6 -1.3 -10.5, 7.7
Myoglobin, 4 hours (μg/L) -60 -146, 27 4 -51, 58
Troponin T, POD1 (μg/L) -0.5a -0.8, -0.1 -0.3a -0.6, -0.1
CK, POD1 (U/L) -250a -497, -2 -120 -352, 112
CK-MB, POD1 (U/L) -9.7 -21.7, 2.4 -4.8 -15.0, 5.4
Myoglobin, POD1 (μg/L) -36 -141, 69 33 -47, 112
4 hours, 4 hours after ICU admission; creatine kinase; CK-MB, creatine kinase, heart muscle tissue;
POD1, first postoperative day. The model is adjusted for age, blood products, baseline value of corresponding cardiac injury marker on ICU admission, and
extracorporeal circulation (ECC) time. The propofol group is the reference. aP < 0.05, statistically significant.
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group, have a better postoperative cardiac function in the
presence of lower troponin I values. Landoni et al. [25],
however, could not show similar results in patients
undergoing mitral valve replacement with a desflurane
preconditioning. Bignami and co-workers [26] did not
assess a difference in postoperative troponin release in
patients with coronary artery disease undergoing mitral
valve surgery with a propofol anesthesia throughout the
surgical procedure versus a sevoflurane anesthesia before
and after CPB (pre- and postconditioning).
The first studies focusing on cardiac postconditioning
were performed in vitro as well as in vivo. Pravdid and his
group [27] showed in an ischemia-reperfusion model of
cardiomyocytes that isoflurane was protective when
applied in reoxygenation. Similarly, in an isolated rat heart
model, postconditioning with sevoflurane attenuated
infarct size and improved cardiac function [28]. De Hert
et al. [11] were able to show cardioprotection with sevo-
flurane postconditioning in patients undergoing CABG
surgery. Hellström et al. [29] performed a postcondition-
ing trial similar to the current one, sedating patients after
CABG surgery with either propofol or sevoflurane for
2 hours only. Results of that trial including patients under-
going CABG surgery with sevoflurane anesthesia and a
postoperative randomization to propofol or sevoflurane
sedation are comparable to those of the current study with
patients after valve replacement: although troponin T
values, measured at 12 hours after surgery, were the same
in both groups, an attenuated statistically significant
increase of troponin T, measured from baseline to peak
values, was observed in the sevoflurane arm.
Whether volatile anesthetics are capable of providing
organ protection in events of clear ischemia-reperfusion
only remains questionable. This may imply myocardial
injury after cardiopulmonary bypass, but also with a myo-
cardial ischemia in the perioperative phase of patients with
cardiac surgery. This topic was extensively discussed and
elegantly summarized in an editorial from De Hert [30].
Another important aspect is the time point of application
of volatile anesthetics in relation to the event of ischemia-
reperfusion, which should not be underestimated. Volatile
anesthetics might induce a protective signaling in the
myocardial cells in defined windows only. Such considera-
tions would also explain the results of the randomized
controlled study performed by Zangrillo et al. [31], in
which conditioning with volatile anesthetics in patients
undergoing noncardiac surgery was not superior to an
anesthesia regimen with propofol. Therefore evidence of
the guidelines from the American College of Cardiology/
American Heart Association [32] recommending volatile
anesthetics for maintenance of general anesthesia in
patients at risk for myocardial events is questionable [33].
Whereas the myocardium-specific marker troponin T
was significantly lower in the sevoflurane arm on the first
postoperative day, no difference could be detected for
CK-MB. This could be due to a different kinetic of these
markers with a faster peak value for the CK-MB compared
with troponin T on injury. Moreover, CK-MB was not
recommended for monitoring patients to detect periopera-
tive myocardial infarction after cardiac surgery. Sensitivity
and specificity of troponin T seem to be superior [34].
This might explain the observed differences in our trial.
Myoglobin values peak within hours after a myocardial
lesion and therefore were not detected at the time points
of 4 hours and POD1. Additionally, myoglobin is not a
reliable parameter for myocardial infarction in general.
Table 4 Linear regression analysis to compare secondary outcomes at different times between the sevoflurane and
propofol groups (n = 102)
Oxygenation index (mm Hg) Unadjusted difference in means
(point estimate)
95% Cl Adjusted difference in means
(point estimate)
95% CI
paO2/FiO2, 4 hours (mm Hg) 21 -5, 48 12 -13, 38
paO2/FiO2, POD1
(mm Hg)
42a 2, 81 27 -9, 64
ICU stay (days) -0.005 -0.6, 0.6 0.07 -0.5, 0.7
Hospital stay (days) -0.4 -1.9, 1.2 -0.2 -1.7, 1.4
Creatinine, POD1 (μM) -3.8 -11.8, 4.1 -1.8 -9.6, 6.0
4 hours, 4 hours after ICU admission; ICU, intensive care unit; POD1, first postoperative day. The model is adjusted for age, blood products, and ECC time. The
propofol group is the reference. aP < 0.05, statistically significant.
Table 5 Logistic regression analysis to compare secondary binary outcomes between the sevoflurane and propofol
groups (n = 102)
Unadjusted OR 95% Cl Adjusted OR 95% CI
Postoperative pulmonary complications 0.4 0.2, 1.1 0.4 0.2, 1.2
PONV 1.4 0.6, 3.0 1.3 0.6, 2.8
PONV, postoperative nausea and vomiting. The model is adjusted for age, blood products, and extracorporeal circulation (ECC) time. The propofol group is the
reference.
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This study confirms the already well-known cardio-
protective properties of sevoflurane as compared with
propofol. Remarkably, and in contrast to all other clini-
cal studies on pharmacologic conditioning with volatile
anesthetics, we have used for the first time a late post-
conditioning protocol exposing patients to low concen-
trations of sevoflurane only in the postoperative phase
and for a relatively short period of 4 hours, whereas
patients in the study of Hellström et al. [29] were also
exposed to sevoflurane during surgery. Application of
volatile anesthetics during surgery might reflect a certain
bias for the study result. In our trial, patients were
exclusively exposed to sevoflurane during the sedation
phase in the ICU for a minimum of 4 hours.
An important aspect of our study that must be con-
sidered is the fact that only biomarkers were analyzed. If
such positive results would claim the potential of being
translated into clinical routine, similar findings from
additional studies would be necessary. Such trials would
require large numbers of patients. Nevertheless, using
biomarkers is certainly a reliable approach for a first
clinical trial, which allows linking the finding with cur-
rent preclinical work including in vitro and animal mod-
els as a first proof of principle.
Propofol is among the most commonly used substances
for sedation in the ICU because it is easily administered
and does not accumulate as do other substances (for
example, benzodiazepines) if used for long-term sedation.
However, because the delivery of volatile anesthetics in
the ICU has become available with the AnaConDa sys-
tem, isoflurane and sevoflurane are new options for seda-
tion of postoperative and critically ill patients. It not only
allows an alternative method of postoperative sedation,
but also might offer new options in selective and delayed
use of organ-protective strategies with ischemia-reperfu-
sion injury. Moreover, postconditioning could be adopted
as a “therapeutic” option to prevent further cell and
organ damage after any kind of injury, such as inflamma-
tion or trauma.
Several potential limitations of the study are acknowl-
edged. First, it is known that the controlled substance
propofol also has protective characteristics. The antiin-
flammatory effect of propofol attenuating cytokine
response has been demonstrated extensively [35,36]. At
least some part of this antiinflammatory effect is also
attributed to its containing ethylenediaminetetraacetic
acid (EDTA), which is an additive in some of the com-
mercially available propofol formulations [37]. However,
these properties would rather have diminished the
observed group differences in cardiac injury markers
and in postoperative pulmonary complications between
sevoflurane and propofol in our trial. From this point of
view, the findings may be even more impressive if
another substance not having possible antiinflammatory
properties had been used for comparison instead of
propofol.
Second, the postconditioning phase was relatively
short (4 hours) and did not exceed this time interval. In
addition, the applied dose of sevoflurane reflecting an
age-adjusted 0.5 MAC was relatively low when com-
pared with anesthetic doses during the operation and
some supraanesthetic concentrations used in precondi-
tioning settings [38]. In this context, the observed
results appear very robust, because higher concentra-
tions of volatile anesthetics could possibly exert even
more pronounced organ-protective effects.
Third, as we were interested only in the per-protocol
data, we did not perform an intention-to-treat analysis,
which would imply a calculation of the data from all
randomized patients, but a per-protocol analysis.
Fourth, although chlorofluorocarbons (CFCs) are firmly
linked with stratospheric ozone depletion and global
atmospheric warming, halogenated anesthetics only con-
tribute for a very small amount of man-made air pollu-
tion with these substances [39]. A widespread use of low-
dose volatile anesthetics for sedation with low flow rates
should reduce the negative impact on the environment
and thereby not influence global warming [40].
Conclusions
The data presented in this investigation suggest that
anesthetic postconditioning with sevoflurane might
mediate cardiac protection, even with the postoperative
application of low-dose sevoflurane. The clinical imple-
mentation of these agents can offer an additional tool in
the treatment or prevention of ischemic organ dysfunc-
tion in the postoperative period. Further studies are
warranted with clinical end points focusing on morbidity
and mortality.
Key messages
• Short application of sevoflurane in the early post-
operative phase decreases troponin T.
• Sedation with a volatile anesthetic in intensive care
units is a possible option to attenuate organ injury.
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